Replimune Group, Inc.: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp. disclosed a stake exceeding 5% in Replimune Group, Inc. via a Schedule 13G filing with the SEC (accession 0000093751-26-000716). The filing signals that the institutional investor has crossed the threshold requiring disclosure under SEC rules. The exact number of shares and percentage held were not specified in the headline disclosure. The move matters because it places State Street among Replimune's significant institutional holders, a status that can draw attention to the clinical-stage biotech's ownership base. Investors will watch for further 13G amendments or 13D filings that could indicate whether the position is passive or active.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
State Street Corp, Replimune Group, Inc.